Wilms Tumor
A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.
Subtype terms (2)
More specific conditions that are subtypes of Wilms Tumor in the MeSH hierarchy.
Drugs by status
Approved for this indication (1)
Phase 4 trials (7)
Phase 3 trials (5)
Phase 2 trials (35)
- retinoic acid
- methylprednisolone
- ly-3023414
- olaparib
- sorafenib
- talazoparib
- bvd-523
- cixutumumab
- selinexor
- etanercept
- erdafitinib
- lorvotuzumab mertansine
- Filgrastim
- nivolumab
- ixabepilone
- larotrectinib
- palbociclib
- ifosfamide
- zarnestra
- ipilimumab
- vemurafenib
- temozolomide
- tazemetostat
- topotecan
- cabozantinib
- Selpercatinib
- tumor-pulsed dendritic cells
- erlotinib
- ivosidenib
- genistein
- +5 more
Phase 1 trials (32)
- simvastatin
- thalidomide
- urea
- busulfan
- prednisone
- enoblituzumab
- 2-o, 3-o desulfated heparin
- hsv-1716
- pazopanib
- pexastimogene devacirepvec
- racotumomab
- ro4929097
- sirolimus
- stem cells
- alemtuzumab
- bortezomib
- vorinostat
- tariquidar
- mesna
- fludarabine
- oxaliplatin
- cisplatin
- gpc3 car-t cell
- melphalan
- alvocidib
- b7-h3 car-t
- galinpepimut-s
- 4-1bbζ egfr806-egfrt
- 4 1bbζ cd19-her2tg
- agar t cells
- +2 more
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (12)
- National Cancer Institute (NCI)
- Children's Cancer and Leukaemia Group
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
- University of Leicester
- University of Michigan
- Wayne State University
- Saarland University
- University of Amsterdam
- Royal Marsden Hospital NHS Trust
- Institut Gustave Roussy
- State University of New York, Buffalo
- Societe Francaise Oncologie Pediatrique
Organization Involved with Phase 2 Indications (12)
- Spectrum Pharmaceuticals
- GlaxoSmithKline
- Inex Pharmaceuticals
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- Cornell University
- Newcastle University
- University of Virginia
- University of Munster
- University of Texas at Houston
- Washington University in St. Louis
- St. Jude Children's Hospital
Organization Involved with Phase 1 Indications (14)
- Laboratorio Elea S.A.C.I.F. y A.
- MacroGenics
- Baylor University
- Emory University
- University of Washington
- New York Medical College
- Ohio State University
- University of Buenos Aires
- University of Cincinnati
- Jennerex Inc.
- Children's National Medical Center
- CURE Childhood Cancer, Inc.
- Government of Spain
- Memorial Sloan-Kettering Cancer Center
Organization Involved with Other Experimental Indications (2)